Search Results - "Tevaarwerk, AJ"

Abstract OT1-02-01: Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer by Sharifi, M, Wisinski, KB, Burkard, ME, Tevaarwerk, AJ, Tamkus, D, Chan, N, Truica, C, Danciu, O, Hoskins, K, O'Regan, RM

“…Background: To date, the use of anti-androgens in the subset of triple negative breast cancers (TNBC) that express androgen receptor (AR) has shown modest…”
Get full text

Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta‐Analysis by Valachis, Antonis, Polyzos, Nikolaos P., Coleman, Robert E., Gnant, Michael, Eidtmann, Holger, Brufsky, Adam M., Aft, Rebecca, Tevaarwerk, Amye J., Swenson, Karen, Lind, Pehr, Mauri, Davide

“…Background. The purpose of the study was to estimate the impact on survival and fracture rates of the use of zoledronic acid versus no use (or delayed use) in…”
Get full text

Abstract P5-13-03: Prospective study of work limitations in breast cancer patients (pts) undergoing curative chemotherapy (CTx) by Tevaarwerk, AJ, Buhr, KA, Conkright, W, Onitilo, A, Robinson, E, Hegeman, R, Ahuja, H, Kwong, RW, Nanad, R, Dennee, A, Koehn, T, Burkard, ME, Wisinski, KB, Wiegmann, DA, Sesto, ME

“…This abstract was withdrawn by the authors…”
Get full text

Abstract P3-02-11: Screening Magnetic Resonance Imaging (MRI) of the breast in women at increased lifetime risk for breast cancer: A retrospective single institution study by Ehsani, S, Strigel, R, Pettke, E, Wilke, L, Szalkucki, L, Tevaarwerk, AJ, Wisinski, KB

“…Background: Multiple factors are associated with an increased lifetime risk of breast cancer, including inheritance of an abnormal BRCA 1/2 gene, history of…”
Get full text

P1-08-01: Survival in Metastatic Breast Cancer (MBC): No Evidence for Improved Survival Following Distant Recurrence after Adjuvant Chemotherapy by Tevaarwerk, AJ, Gray, R, Schneider, BP, Smith, ML, Wagner, LI, Miller, KD, Sparano, JA

“…Population-based studies have suggested improved survival for patients diagnosed with MBC in recent years, presumably due to the availability of new and more…”
Get full text

Abstract P2-14-07: Predictors of Employment Outcomes in Breast Cancer (BrCa) Patients: An Analysis from E2Z02 (ECOG's SOAPP Study) by Tevaarwerk, AJ, Lee, J-w, Sesto, MC, Cleeland, CS, Wagner, LI, Chang, VTS, Fisch, M.

“…Cancer survivors are more likely to be unemployed than healthy counterparts (de Boer et al, JAMA 2009). BrCa patients comprise roughly one-fourth of the…”
Get full text

Abstract P6-12-02: Use of cytochrome P450 interacting medications in the setting of adjuvant therapy for breast cancer by Njiaju, UO, Kolesar, JM, Johnston, SA, Eickhoff, JC, Osterby, KR, Poggi, LE, Tevaarwerk, AJ, Millholland, RJ, Oliver, KA, Heideman, JL, Wisinski, KB

“…Background: In the current era of personalized medicine, oral targeted therapies are increasingly used in cancer treatment. In breast cancer, oral…”
Get full text

Abstract P2-11-15: Development of a web-based survey tool to assess change in breast cancer (BrCa) survivor knowledge after receipt of cancer treatment summary and survivorship care plan (SCP) by Custer, JL, Rocque, GB, Wisinski, KB, Jones, NR, Donohue, S, Koehn, TM, Champeny, TL, Terhaar, AR, Chen, KB, Peck, KA, Tun, MT, Wiegmann, DA, Sesto, ME, Tevaarwerk, AJ

“…Intro: The Institute of Medicine advocates survivorship care plans (SCPs) as tools to improve coordination of care by improving survivor knowledge of follow-up…”
Get full text

P5-18-12: Perception, Practice and Toxicity of Adjuvant Treatment of HER2+ Breast Cancer in Wisconsin by Rocque, GB, Onitilo, AA, Engel, JM, Pettke, EN, Boshoven, AM, Zhang, S, Kim, KM, Rishi, S, Waack, B, Wisinski, KB, Tevaarwerk, AJ, Burkard, ME

“…INTRODUCTION: Multiple trastuzumab-containing (neo)adjuvant regimens are used for HER2+ BrCa, but the experience with these regimens in routine practice is not…”
Get full text